Author

J. M. Mesfin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

F. White· 2 shared L. E. Stopfer· 2 shared B. A. Joughin· 1 shared B. D. Bryson· 1 shared D. A. Lauffenburger· 1 shared E. Brown· 1 shared J. A. Wells· 1 shared N. Rettko· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. White

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas

L. E. Stopfer, N. Rettko, O. Leddy, J. M. Mesfin, E. Brown, S. Winski, B. D. Bryson, J. A. Wells, F. White

This study shows MEK inhibition increases MHC-I antigen presentation in melanoma, enhancing immunotherapy efficacy through targeted epitopes.

bioRxiv · Jan 10, 2022Cancer Biology

Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition

L. E. Stopfer, J. M. Mesfin, B. A. Joughin, D. A. Lauffenburger, F. White

This study uses a novel immunopeptidomics approach to quantify MHC I repertoire changes induced by CDK4/6 inhibition and interferon gamma in melanoma.

bioRxiv · Mar 3, 2020Immunology